FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat (FG-4592), is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis.
I have been working at FibroGen full-time
Variety of drug development programs, fairly good benefits with respect to paid time off. ESPP and 401K matching
Little transparency about key decisions, risk averse, poor processes for budgeting and project management
Advice to Management
Improve communication to employees, take a more even-handed approach to promotions, improve processes for budgeting
I applied through a staffing agency. The process took 4+ weeks. I interviewed at FibroGen in May 2014.
The interview process was very quick. I had a phone interview with the QC Senior Director and my onsite interview was scheduled the same day. A lot of technical questions and some behavioural questions. The hiring process took 1 month.
Let us know if we're missing any workplace or industry recognition –